01—Abstract
Summary
Summary of the 8-K filed June 16, 2025. Cited figures are marked; the original filing is the authoritative source.
Becton, Dickinson and Company (BDX) filed this Form 8-K on June 16, 2025 to furnish a Notice of Pendency and Proposed Settlement of a consolidated stockholder derivative action (In re Becton, Dickinson and Company Stockholder Derivative Litigation, D.N.J., together with the related Lotz v.
Burzik state court action). The filing is a Regulation FD disclosure, not a financial results report, and it contains no new earnings, guidance, or balance sheet information. The derivative suits alleged that officers and directors made misleading statements between November 2019 and February 2020 about software defects and FDA scrutiny of the Alaris infusion pump system, and that they harmed the company as a result.
Defendants deny all wrongdoing. The proposed settlement provides for a $9.0 milliona payment from directors' and officers' insurance carriers into a settlement fund, which would flow to the company after plaintiffs' counsel fees (requested at $3.47 million) and notice costs are paid. BD has also agreed to adopt corporate governance modifications within 60 days of final approval, to be maintained for at least four years.
Because this is a derivative action, no class-wide monetary payment goes to shareholders. The Court is scheduled to hold a settlement hearing on August 11, 2025, and the settlement remains subject to court approval and the satisfaction of conditions in the stipulation. For investors, the filing is primarily a governance and litigation-closure event.
The monetary recovery is modest relative to the company's size, and the principal economic effect is the removal of an overhang from the Alaris-related litigation, paired with stronger governance commitments. Investors should watch the August 2025 hearing and any objections for final resolution.
02—Key points
Key Highlights
- Settles the consolidated federal stockholder derivative action and related New Jersey state court action tied to alleged misstatements about Alaris infusion pump software defects and FDA scrutiny (Nov 2019 to Feb 2020).
- Settlement consideration includes a $9.0 million payment from BD's directors' and officers' insurance carriers, with the net balance released to the company after fees and costs.
- Plaintiffs' counsel will request $3.47 million in attorneys' fees and expenses, paid by defendants subject to court approval; service awards capped at $5,000 each.
- BD agrees to adopt corporate governance modifications within 60 days of final approval and maintain them for at least four years.
- Settlement Hearing scheduled for August 11, 2025, before Judge Stanley R. Chesler in the U.S. District Court for the District of New Jersey; the court may approve without a hearing or move it to a virtual format.
- Defendants, including current and former officers and directors, deny all wrongdoing; the court has made no findings on the merits.
- The filing is a Regulation FD disclosure furnished under Item 7.01 and contains no new financial results, guidance, or operating metrics.
03—Questions
Frequently Asked Questions
Does this settlement involve a payment to BD shareholders?
No. This is a derivative action brought on behalf of the company, not a class action, so there is no common fund for shareholders to claim. The $9.0 million is paid to the company by insurance carriers, and the notice states that the balance of the settlement fund, after fees and costs, is released to BD.
How significant is the $9.0 million settlement to BD's financials?
The notice does not provide BD's financial impact, but $9.0 million is small relative to a company of BD's size. Because the payment comes from D&O insurance and the filing contains no financial statement information, it is unlikely to be material to earnings. Investors should check the company's periodic reports for any accounting treatment.
What are the governance modifications BD agreed to?
The notice refers to Governance Modifications set out in Exhibit A to the Stipulation, which the company must adopt within 60 days after the court's final approval and maintain for at least four years. The specific terms are not described in this notice and would need to be reviewed in the Stipulation itself.
What happens next in the litigation?
The court will hold a Settlement Hearing on August 11, 2025, to decide whether the settlement is fair, reasonable, and adequate and whether to approve the attorneys' fees. Stockholders who wish to object must file written objections at least 14 days before the hearing. If the court approves the settlement and conditions are met, the derivative action will be dismissed with prejudice.
Does the settlement indicate that BD admits wrongdoing?
No. All defendants expressly deny any wrongdoing or liability, and the court has made no findings on the merits. The notice states that the settlement was reached to avoid the burden, expense, and risk of continued litigation.
04—Continue